Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Proxalutamide  COVID-19 treatment studies for Proxalutamide  C19 studies: Proxalutamide  Proxalutamide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Other Treatments Global Adoption
Outcomes in COVID-19 proxalutamide studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
All studies   Mortality   Ventilation   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 78% 4 1,953 Improvement, Studies, Patients Relative Risk Mortality 78% 4 1,953 Ventilation 95% 2 445 Hospitalization 72% 4 1,953 Viral clearance 74% 1 0 RCTs 78% 4 1,953 RCT mortality 78% 4 1,953 Peer-reviewed 78% 2 1,046 Early 71% 3 1,175 Late 78% 1 778 Proxalutamide for COVID-19 c19proxalutamide.com May 2022 Favorsproxalutamide Favorscontrol
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION HOSPITALIZATION VIRAL CLEARANCE RCTS RCT MORTALITY PEER-REVIEWED All Early Late Proxalutamide for COVID-19 C19PROXALUTAMIDE.COM MAY 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% improvement Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% improvement All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% improvement 4 proxalutamide COVID-19 studies c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] 0/365 1/365 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% improvement Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% improvement All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% improvement 4 proxalutamide COVID-19 mortality results c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 97% 0.03 [0.00-0.47] 0/134 17/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 90% 0.10 [0.01-1.84] 0/75 5/102 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0043 Early treatment 95% 0.05 [0.01-0.40] 0/209 22/236 95% improvement All studies 95% 0.05 [0.01-0.40] 0/209 22/236 95% improvement 2 proxalutamide COVID-19 mechanical ventilation results c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0043 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 91% 0.09 [0.03-0.27] hosp. 3/134 35/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 86% 0.14 [0.03-0.60] hosp. 2/75 19/102 Kintor (DB RCT) 50% 0.50 [0.15-1.65] hosp. 4/365 8/365 Tau​2​ = 0.47, I​2​ = 53.4%, p = 0.002 Early treatment 81% 0.19 [0.07-0.54] 9/574 62/601 81% improvement Cadegiani (DB RCT) 33% 0.67 [0.54-0.82] hosp. time 423 (n) 355 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0001 Late treatment 33% 0.67 [0.54-0.82] 0/423 0/355 33% improvement All studies 72% 0.28 [0.10-0.81] 9/997 62/956 72% improvement 4 proxalutamide COVID-19 hospitalization results c19proxalutamide.com May 2022 Tau​2​ = 0.87, I​2​ = 80.5%, p = 0.019 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% improvement Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% improvement All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% improvement 4 proxalutamide COVID-19 serious outcomes c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani (DB RCT) 45% 0.55 [0.49-0.62] no recov. 423 (n) 355 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 45% 0.55 [0.49-0.62] 0/423 0/355 45% improvement All studies 45% 0.55 [0.49-0.62] 0/423 0/355 45% improvement 1 proxalutamide COVID-19 recovery result c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Kintor (DB RCT) 74% 0.26 [0.13-0.51] viral+ n/a n/a Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Early treatment 74% 0.26 [0.13-0.51] 74% improvement All studies 74% 0.26 [0.13-0.51] 74% improvement 1 proxalutamide COVID-19 viral clearance result c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% improvement Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% improvement All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% improvement 4 proxalutamide COVID-19 Randomized Controlled Trials c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] 0/134 2/134 Improvement, RR [CI] Treatment Control Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] 0/75 1/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] 0/365 1/365 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.18 Early treatment 71% 0.29 [0.05-1.75] 0/574 4/601 71% improvement Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% improvement All studies 78% 0.22 [0.17-0.30] 45/997 175/956 78% improvement 4 proxalutamide COVID-19 RCT mortality results c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.3 Early treatment 80% 0.20 [0.01-4.13] 0/134 2/134 80% improvement Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Late treatment 78% 0.22 [0.16-0.30] 45/423 171/355 78% improvement All studies 78% 0.22 [0.16-0.30] 45/557 173/489 78% improvement 2 proxalutamide COVID-19 peer reviewed trials c19proxalutamide.com May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p < 0.0001 Effect extraction pre-specified(most serious outcome) Favors proxalutamide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ McCoy (DB RCT) 80% 0.20 [0.01-4.13] death 0/134 2/134 Improvement, RR [CI] Treatment Control McCoy (DB RCT) 97% 0.03 [0.00-0.47] ventilation 0/134 17/134 McCoy (DB RCT) 91% 0.09 [0.03-0.27] hosp. 3/134 35/134 Cadegiani (DB RCT) 63% 0.37 [0.02-8.85] death 0/75 1/102 Cadegiani (DB RCT) 90% 0.10 [0.01-1.84] ventilation 0/75 5/102 Cadegiani (DB RCT) 86% 0.14 [0.03-0.60] hosp. 2/75 19/102 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/365 1/365 Kintor (DB RCT) 50% 0.50 [0.15-1.65] hosp. 4/365 8/365 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/360 1/361 Kintor (DB RCT) 71% 0.29 [0.06-1.37] hosp. 2/360 7/361 Kintor (DB RCT) 67% 0.33 [0.01-8.16] death 0/346 1/347 Kintor (DB RCT) 92% 0.08 [0.00-1.36] hosp. 0/346 6/347 Kintor (DB RCT) 74% 0.26 [0.13-0.51] viral+ n/a n/a Cadegiani (DB RCT) 78% 0.22 [0.16-0.30] death 45/423 171/355 Cadegiani (DB RCT) 79% 0.21 [0.15-0.30] death 34/423 138/355 Cadegiani (DB RCT) 45% 0.55 [0.49-0.62] no recov. 423 (n) 355 (n) Cadegiani (DB RCT) 55% 0.45 [0.39-0.52] no recov. 423 (n) 355 (n) Cadegiani (DB RCT) 33% 0.67 [0.54-0.82] hosp. time 423 (n) 355 (n) proxalutamide COVID-19 outcomes c19proxalutamide.com May 2022 Favors proxalutamide Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Share
Tweet
@CovidAnalysis
FAQ
Public domain CC0 1.0